Galimedix, Inc. | WebDisclosure

PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 1 month ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy
BRIEF

published on 12/05/2024 at 13:33, 1 year 2 months ago

Galimedix Therapeutics lance une étude de phase 1 avec le GAL-101 oral

Étude De Phase 1 La Maladie D'Alzheimer GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 12/05/2024 at 13:33, 1 year 2 months ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 1 year 2 months ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 1 year 8 months ago

Galimedix Therapeutics réunit son conseil consultatif scientifique pour l'étude de phase 2 du GAL-101

Étude Clinique De Phase 2 Conseil Consultatif Scientifique GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 06/10/2024 at 14:05, 1 year 8 months ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 1 year 8 months ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 1 year 11 months ago

Galimedix Therapeutics dévoile des données prometteuses sur le traitement de la maladie d'Alzheimer à l'occasion de l'AD/PD™ 2024

Développement Clinique GAL-201 La Maladie D'Alzheimer Effets Neuroprotecteurs Fonction Cognitive
BRIEF

published on 03/08/2024 at 10:05, 1 year 11 months ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
PRESS RELEASE

published on 03/08/2024 at 10:00, 1 year 11 months ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024

Published on 02/20/2026 at 18:30, 1 hour 45 minutes ago

Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 30 minutes ago

Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 5 hours 45 minutes ago

Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 6 hours 7 minutes ago

Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 6 hours 15 minutes ago

Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 1 hour 38 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 hour 44 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 1 hour 52 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 46 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 46 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 2 hours 40 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News